Our work
>

Medicines

We develop and deliver new medicines that address neglected diseases

Moxidectin for onchocerciasis (river blindness)

On 13 June 2018, MDGH obtained United States Food and Drug Administration (FDA) approval for moxidectin (an anthelmintic) for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older.

The development of moxidectin was previously steered by a partnership between the World Health Organization Special Programme for Research and Training in Tropical Diseases (TDR) and Wyeth/Pfizer since the 1990s. When Pfizer ended the collaboration in 2011, the development of moxidectin was driven exclusively by TDR until MDGH licensed it in 2014.

Moxidectin is not approved or licensed for human use in all countries where this website is accessible.

For more information about moxidectin for the treatment of river blindness please read the US prescribing information below.

Adverse event reporting

The safety of our medicines and the wellbeing of our patients is our highest priority. To report adverse events involving MDGH medicines, please contact our global pharmacovigilance team.
Email: SAE@medicinesdevelopment.com